Global Investments in compelling Biotech
and Med-Tech discoveries
Meaningful outcomes require long term scalable vision.
Who we are
We are a European family office owned fund; we understand biosciences and medical technologies better than anyone else in the Private Equity and Venture Capital ecosystem. The capital of this fund has been generated by the family office's active bioscience investments across Europe, USA, and the APAC region since 1995. We understand the intricacies of commercializing bioscience discoveries. We also acknowledge that bioscience venture leadership requires deep courage—from founders and the investors that back them.
What we look for
We operate globally and only review investment opportunities submitted to us by our partner investment banks across the globe. If we believe in the transformative power of the discovery and the founder's ambition, this will suffice for us to determine the venture's potential.
Our approach
Upon receipt of a proposal from our investment bank partners, we will analyze the proposed deal, meet with the venture founders, and understand their vision. We will propose a deal size and structure.
Execute a letter of intent and perform appropriate due diligence, negotiate, and execute a mutually acceptable binding contract.
Release the required funding, close the transaction and work together to grow the business.
Our consortium
Antisoma Venture Capital Fund S.A. operates within a broader institutional ecosystem through its strategic alignment with Bioscience Equity Partners and a consortium of Middle Eastern and Asian sovereign and quasi-sovereign institutional investors. This structure provides access to long-duration, patient capital and regional strategic reach, supported by disciplined investment governance.
The Fund’s investment approach is shaped by rigorous scientific and commercial evaluation, reflecting deep expertise across clinical development, capital formation, and life sciences investment, and underpinning a long-term, methodical deployment strategy.
The Fund benefits from the strategic oversight of Dr. George Syrmalis.